From:  Targeting cytoskeletal phosphorylation in cancer

Main human NMII (RLC, ELC and MHCII-A, B, C) phosphorylation sites

GeneSitePutative kinaseDiscovered by/inhibitorEffectReferences
MYL9/MYL12Ser1/2PKCαTargeted mutationInhibits ATPase activity[32, 33]
Thr18CITK, ZIPK, ROCK1/2Targeted mutation, biochemical assaysSynergizes with pSer19 to stabilize conformation and boost ATPase activity[38, 109]
Ser19MLCK, MRCK, CITK, ZIPK, ROCK1/2ML-7, dominant negatives, Y-27632, siRNAConformational extension and increased ATPase activity[35, 110]
Tyr155EGFRTargeted mutation, cetuximabInhibited NMII assembly[37]
MYL6Tyr29not knownnot knownCarcinoma progression[111]
Tyr89EGFR?Genfitinibnot known[41]
MYH9Tyr158SrcsiRNADecreases listeria infection[112]
Thr1800, Ser1803, Ser1808TRPM6/7Biochemical assaysDecreases filament stability[43]
Ser1916PKCβGo6976Decreases filament stability, increases Mts1 binding[45]
Ser1943CK-IITargeted mutationDecreases filament formation[47]
MYH10Ser1810, Thr1815TRPM6/7Biochemical assaysDecreases filament stability[43]
Ser1935PKCζTargeted mutation, PKCζ pseudosubstrateImpairs filament stability and cell polarity[49]
Ser1937PKCζBiochemical assays, siRNAImpairs filament stability[48]
MYH14Thr1832/1838TRPM6/7Biochemical assaysDecreases filament stability[43]
Return to article view

PKCs: protein kinase C; ROCK: RhoA-coiled coil kinase; MLCK: myosin light chain kinase; CITK: citron kinase; MRCK: myotonic dystrophy kinase-related; ZIPK: zipper-interacting protein kinase; siRNA: small interfering RNA; TRPM6/7: transient receptor potential melastatin 6/7